Holen Sie sich die Stockscreener-App
278.76
1.71%
-4.85
Handel nachbörslich:
278.76
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$283.61
Offen:
$279.38
24-Stunden-Volumen:
3.03M
Relative Volume:
1.60
Marktkapitalisierung:
$149.00B
Einnahmen:
$32.53B
Nettoeinkommen (Verlust:
$4.23B
KGV:
19.81
EPS:
14.07
Netto-Cashflow:
$6.28B
1W Leistung:
-13.38%
1M Leistung:
-13.34%
6M Leistung:
-10.79%
1J Leistung:
+5.04%
1-Tages-Spanne:
$276.56
$281.36
1-Wochen-Bereich:
$276.56
$321.22
52-Wochen-Spanne:
$260.52
$346.85
Amgen Inc Stock (AMGN) Company Profile
Firmenname
Amgen Inc
Sektor
Telefon
(805)447-1000
Adresse
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Vergleichen Sie AMGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| AMGN | 278.76 | 149.00B | 32.53B | 4.23B | 6.28B | 14.07 |
| LLY | 727.20 | 683.37B | 40.86B | 8.37B | -2.28B | 5.4193 |
| NVO | 99.81 | 446.14B | 39.36B | 13.79B | 9.83B | 2.4077 |
| JNJ | 154.77 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
| ABBV | 166.28 | 293.80B | 55.53B | 5.12B | 15.62B | 3.65 |
| MRK | 96.56 | 242.49B | 63.17B | 12.15B | 14.84B | 1.80 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-28 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Hochstufung | Truist | Hold → Buy |
| 2023-10-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-17 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-10-11 | Fortgesetzt | BofA Securities | Neutral |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-24 | Bestätigt | Oppenheimer | Outperform |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | Bestätigt | Truist | Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Underperform |
| 2022-10-31 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-10-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-09 | Bestätigt | Barclays | Equal Weight |
| 2022-02-09 | Bestätigt | Jefferies | Buy |
| 2022-02-09 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2022-02-09 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-09 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-09-23 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | Eingeleitet | Daiwa Securities | Buy |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | Hochstufung | Truist | Hold → Buy |
| 2020-10-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | Herabstufung | Truist | Buy → Hold |
| 2020-10-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | Fortgesetzt | Guggenheim | Neutral |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-03-30 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-17 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-05-23 | Hochstufung | Citigroup | Neutral → Buy |
Alle ansehen
Amgen Inc Aktie (AMGN) Neueste Nachrichten
Amgen Sells Off: Keep Calm And Buy The Dip (NASDAQ:AMGN) - Seeking Alpha
Napa Wealth Management Acquires New Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Is Amgen Inc. (AMGN) the Best Immunotherapy Stock to Buy Now? - Insider Monkey
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Aljian Capital Management LLC Grows Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Short Interest Update - MarketBeat
Thrivent Financial for Lutherans Trims Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Swiss National Bank Grows Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Atlanta Consulting Group Advisors LLC Makes New $796,000 Investment in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Natixis Advisors LLC Has $94.32 Million Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Sawgrass Asset Management LLC Sells 11,850 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
GSA Capital Partners LLP Takes Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Kinsale Capital Group Inc. Raises Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Mizuho Securities USA LLC Has $25.16 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Kentucky Retirement Systems Has $12.06 Million Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
2 Reasons to Buy Amgen Stock, and 1 Reason to Be Cautious - MSN
Northcape Wealth Management LLC Increases Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
The three-year decline in earnings for Amgen NASDAQ:AMGN) isn't encouraging, but shareholders are still up 50% over that period - Yahoo Finance
AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Amgen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Amazon.com Inc., Amgen share losses lead Dow's 275-point drop - MSN
Dow falls nearly 400 points on losses for shares of Amgen, Amazon.com Inc. - MSN
Amgen, Amazon.com Inc. share losses lead Dow's 288-point drop - MSN
A Journey of Courage: Empowering Others with Gastric Cancer - Marketscreener.com
Amgen Inc (AMGN) Stock Price, Trades & News - GuruFocus.com
Merck, Amgen share losses lead Dow's 168-point drop - MarketWatch
Amgen (NASDAQ:AMGN) Coverage Initiated by Analysts at Wolfe Research - MarketBeat
Amgen (NASDAQ:AMGN) Stock Rating Upgraded by Citigroup - MarketBeat
Amgen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024 - PR Newswire
Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate - Yahoo Finance
ING Groep NV Reduces Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
2 Dividend Stocks to Buy Hand Over Fist in November - The Motley Fool
Curi RMB Capital LLC Sells 1,681 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Zions Bancorporation N.A. Has $5.27 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
KBC Group NV Raises Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen speaks out about bone density concerns with obesity drug - Clinical Trials Arena
Is Wall Street Bullish or Bearish on Amgen Stock? - Nasdaq
Amgen (NASDAQ:AMGN) Coverage Initiated at Citigroup - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Bell Bank - MarketBeat
Is Wall Street Bullish Or Bearish On Amgen Stock? - Barchart
Citi sets Amgen neutral with $335 target on MariTide focus - Investing.com
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Amgen's SWOT analysis: biotech giant's stock faces obesity market opportunity - Investing.com
MOORE LAW ENCOURAGES AMGEN INC. INVESTORS TO CONTACT LAW FIRM - PR Newswire
Amgen dismisses bone density concerns related to its weight-loss drug - Reuters
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density - Benzinga
Understanding Cardiovascular Risk: The Role of LDL-C, Comorbidities and Early Intervention - Amgen
BRIEF—Amgen dismisses obesity drug safety concern; investors unsure - The Pharma Letter
Amgen To Present At 2024 UBS GLOBAL HEALTHCARE CONFERENCE; Webcast At 1:15 PM ET - Nasdaq
Finanzdaten der Amgen Inc-Aktie (AMGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):